Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Skingenix, Inc.
This is a phase II, randomized, controlled, multi-center study designed to assess the safety and efficacy of MEBO in the treatment of subjects with DFUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ≥18 years of age
Able and willing to provide informed consent
Able and willing to comply with protocol visits and procedures
Target ulcer duration of ≥4 weeks
You may not be if
Ulcer of a non-diabetic pathophysiology
Known or suspected allergies to any of the components of MEBO
